MannKind's CEO Discusses Q1 2012 Results - Earnings Call Transcript

MannKind (MNKD)

Q1 2012 Earnings Call

May 09, 2012 5:00 pm ET

Executives

Matthew J. Pfeffer - Chief Financial Officer, Principal Accounting Officer and Corporate Vice President

Hakan S. Edstrom - President, Chief Operating Officer and Director

Alfred E. Mann - Founder, Chairman and Chief Executive Officer

Analysts

Karen E. Jay - JP Morgan Chase & Co, Research Division

Matthew W. Luchini - Piper Jaffray Companies, Research Division

Tazeen Ahmad

Presentation

Operator

Ladies and gentlemen, thank you for standing by. Welcome to the MannKind Corporation First Quarter 2012 Conference Call. [Operator Instructions] As a reminder, this call is being recorded today, May 9, 2012. Joining us today from MannKind are Chairman and CEO, Alfred Mann; President and COO, Hakan Edstrom; and Chief Financial Officer, Matthew Pfeffer. I would now like to turn the call over to Matthew Pfeffer, Chief Financial Officer of MannKind Corporation. Please go ahead.

Matthew J. Pfeffer

Good afternoon, and welcome, and thank you for participating in today's call. I'll summarize our financial results for the first quarter of 2012 as reported earlier today. Then Hakan will discuss our current operations, and Al will conclude with an overview before we open up the call to your questions.

Before we proceed further, please note that comments made during this call will include forward-looking statements within the meaning of federal securities laws. It is possible that the actual results could differ from these stated expectations. For factors which could cause actual results to differ from expectations, please refer to the reports filed by the company with the Securities and Exchange Commission under the Securities and Exchange Act (sic) [Securities Exchange Act] of 1934.

If you liked this article you might like

Pharma Bro Martin Shkreli Awaits Jury Decision in Fraud Case

Mannkind in Free Fall After Changes to Insulin Product, Sales Force

Mannkind Stock Drops Following Changes to Its Insulin Product

Laser-Maker Cynosure Leads Biotech Movers Ahead of Market Open

Insulin Drug Offers Hope for MannKind